Artelo Expands ART27.13 into Glaucoma with Fully Funded Study
Event summary
- Artelo Biosciences partners with Belfast Health and Social Care Trust for a fully funded study on ART27.13 in glaucoma patients.
- Glaucoma UK and HSC R&D Division provide funding for the investigator-initiated study.
- First patient enrollment anticipated in Q2 2026.
- ART27.13, a peripherally selective synthetic cannabinoid, aims to modulate intraocular pressure without central nervous system effects.
- Study led by Professor Augusto Azuara-Blanco, a globally recognized authority in glaucoma management.
The big picture
Artelo's move into glaucoma with ART27.13 reflects a strategic pivot towards leveraging its peripherally selective cannabinoid for multiple indications. The fully funded study underscores the growing interest in cannabinoid-based therapies for ophthalmologic conditions, particularly as existing treatments face adherence and efficacy challenges. This expansion could enhance ART27.13's value proposition beyond its lead indication in cancer-related anorexia, potentially attracting broader investor and partner interest.
What we're watching
- Therapeutic Expansion
- Whether ART27.13 can successfully transition from cancer-related anorexia to ophthalmology, broadening its market potential.
- Clinical Efficacy
- The pace at which preliminary data from the glaucoma study could influence ART27.13's development timeline and investor sentiment.
- Capital Efficiency
- How Artelo's strategy of leveraging third-party funded studies impacts its financial flexibility and pipeline progression.
Related topics